In May 2013, the influential magazine Forbes interviewed the founder of the company Nervostrong Medica. Forbes estimated that the pharmaceutical company had achieved turnover exceeding EUR 1,000,000 with only three products in the relatively short interval of three years. The key players in the medicine market have been able to earn EUR 5,000,000 extra over the past five years. These results were achieved in the relatively small pharmaceutical market of Latvia.